Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 16, 1999

View Archived Issues

rhIL-11 tested in active Crohn's disease

Pharmacological characteristics of PK inhibitor CGP-41251 explored

Cypros receives additional notice of allowance concerning U.S. patent on Cordox

Teva's tender offer to acquire Copley expires

Seragen sublicenses daclizumab patents to Roche

Genzyme Molecular Oncology announces initiation of breast cancer vaccine trial

UroCor and Mallinckrodt enter marketing agreement for brachytherapy implants

M-Vax nearing commercialization in several markets

BASF's new ET antagonists described in patent literature

Warner-Lambert discloses new IL-8 (CXCR1/CXCR2) receptor antagonists

Novel biaryl compounds for herpesvirus infections identified by Tularik researchers

Benzimidazole COX-2 inhibitors in development at Pfizer

Human factor Xa inhibitors under evaluation at Roche Diagnostics

Solvay scientists describe new motilin agonists derived from erythromycin

Faes researches piperazine-based atypical antipsychotics

BBI Biotech receives three SBIR grants

Potential new use of nefiracetam profiled at 23rd IEC meeting

Boehringer Ingelheim's TNF-alpha-1a launched in Europe for soft tissue sarcoma

Sacricin characterized as potential novel antiepileptic in preclinical and early clinical studies

German company obtains renal cell carcinoma MAb license from Centocor

AstraZeneca and Knoll establish marketing agreement for Reductil

Novel bifunctional compound BN-80933 provides remarkable neuroprotection in several tests

DuPont seeks European approval for ultrasound contrast agent

K(ATP) channel opener with improved cardioprotective efficacy designed at BMS

New transdermal drug delivery system receives U.S. patent coverage

Sonata clears final regulatory step for marketing in the U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.